Salmeterol
Brand names: Serevent
Salmeterol is a long-acting beta-2 agonist (LABA) for maintenance bronchodilation in asthma and COPD; in asthma it must always be used with an inhaled corticosteroid, never alone.
Adult dose
Dose adjustments
No need to adjust the dose in patients with impaired renal function.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to salmeterol xinafoate or to any of the excipients
Side effects
- Headache (common)
- Tremor (common)
- Palpitations (common)
- Muscle cramps (common)
- Tachycardia (uncommon)
Clinical monograph
How it works
It is a long-acting β2-adrenoceptor agonist relaxing airway smooth muscle for around 12 hours, with a slower onset than salbutamol.
Prescribing in practice
- In asthma, LABA monotherapy is unsafe — always give it with an inhaled corticosteroid (usually a combination inhaler).
- It is a maintenance treatment, not a reliever for acute symptoms.
- Tremor, palpitations and (at high doses) hypokalaemia can occur.
Monitoring
Review asthma/COPD control, inhaler technique and reliever use.
Counselling the patient
- It is a regular preventer, not for sudden breathlessness — keep your reliever for that.
- In asthma, never use it without your steroid inhaler.
- It works more slowly than your blue reliever.
Evidence & guidelines
LABAs are add-on maintenance therapy in asthma (always with an ICS) and in COPD per NICE NG80/NG115.
Reference: NICE NG80/NG115; BTS/SIGN; MHRA; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024